JP2017535592A5 - - Google Patents

Download PDF

Info

Publication number
JP2017535592A5
JP2017535592A5 JP2017528854A JP2017528854A JP2017535592A5 JP 2017535592 A5 JP2017535592 A5 JP 2017535592A5 JP 2017528854 A JP2017528854 A JP 2017528854A JP 2017528854 A JP2017528854 A JP 2017528854A JP 2017535592 A5 JP2017535592 A5 JP 2017535592A5
Authority
JP
Japan
Prior art keywords
composition
active agent
use according
coating
weight percent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017528854A
Other languages
English (en)
Japanese (ja)
Other versions
JP6686023B2 (ja
JP2017535592A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/002345 external-priority patent/WO2016083891A1/en
Publication of JP2017535592A publication Critical patent/JP2017535592A/ja
Publication of JP2017535592A5 publication Critical patent/JP2017535592A5/ja
Application granted granted Critical
Publication of JP6686023B2 publication Critical patent/JP6686023B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017528854A 2014-11-25 2015-11-25 生物活性剤または生物活性剤類を送達する組成物および方法 Expired - Fee Related JP6686023B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462084387P 2014-11-25 2014-11-25
US62/084,387 2014-11-25
PCT/IB2015/002345 WO2016083891A1 (en) 2014-11-25 2015-11-25 Compositions and methods for delivering a bio-active agent or bio-active agents

Publications (3)

Publication Number Publication Date
JP2017535592A JP2017535592A (ja) 2017-11-30
JP2017535592A5 true JP2017535592A5 (https=) 2019-01-10
JP6686023B2 JP6686023B2 (ja) 2020-04-22

Family

ID=56073684

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017528854A Expired - Fee Related JP6686023B2 (ja) 2014-11-25 2015-11-25 生物活性剤または生物活性剤類を送達する組成物および方法

Country Status (7)

Country Link
US (3) US10471070B2 (https=)
EP (1) EP3223793B1 (https=)
JP (1) JP6686023B2 (https=)
KR (1) KR102511830B1 (https=)
CN (1) CN107645951B (https=)
CA (1) CA2968926C (https=)
WO (1) WO2016083891A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018220444A2 (en) * 2017-05-30 2018-12-06 Eximore Ltd. Compositions and methods for treating dry eye syndrome delivering antibiotic macrolide
CN111110636B (zh) * 2018-11-01 2022-09-27 复旦大学附属眼耳鼻喉科医院 使用纳米介孔氧化硅高效负载及缓释抗青光眼药物
US12447045B2 (en) 2019-10-02 2025-10-21 Segal Innovations LLC Bio-adhesive dissolving compounds and device
US11207267B2 (en) 2019-10-02 2021-12-28 Segal Innovations LLC Bio-adhesive dissolving compounds and device
MX2022006803A (es) * 2019-12-04 2022-09-19 Restore Vision Llc Formulaciones oftalmicas para el tratamiento de la presbicia.
WO2022096931A2 (en) * 2020-11-09 2022-05-12 Eximore Ltd. Punctal plugs containing micelle-encapsulated ophthalmic pharmaceuticals and methods for making thereof
EP4346720A4 (en) 2021-05-28 2025-01-01 Sight Sciences, Inc. INTRAOCULAR DEVICES, SYSTEMS AND METHODS

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
DE1300150T1 (de) 1988-09-06 2003-09-18 Pharmacia Ab, Stockholm Prostaglandin-Derivate zur Behandlung von Glaukom oder Augenüberdruck
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JP4000505B2 (ja) 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
EP2004172B1 (en) * 2006-03-31 2019-03-13 Mati Therapeutics Inc. Drug delivery structures and compositions for nasolacrimal system
CN101505695A (zh) * 2006-06-21 2009-08-12 庄臣及庄臣视力保护公司 用于递送活性试剂的泪点塞
UY30883A1 (es) 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
AU2008300013A1 (en) 2007-09-07 2009-03-19 Qlt Inc. Drug cores for sustained release of therapeutic agents
EP2320972B1 (en) * 2008-05-08 2020-07-01 MiniPumps, LLC Implantable drug-delivery devices
US9095404B2 (en) * 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
EP2303184A4 (en) * 2008-06-24 2013-06-19 Quadra Logic Tech Inc COMBINATION TREATMENT OF GREEN STAR
US20100158980A1 (en) * 2008-12-18 2010-06-24 Casey Kopczynski Drug delivery devices for delivery of therapeutic agents
CA2798084A1 (en) * 2010-05-17 2011-11-24 Aerie Pharmaceuticals, Inc. Drug delivery devices for delivery of ocular therapeutic agents
US20120238994A1 (en) * 2010-12-22 2012-09-20 Martin Nazzaro Two-piece injectable drug delivery device with heat-cured seal
US20120276186A1 (en) 2011-04-29 2012-11-01 Ghebremeskel Alazar N Sustained release latanoprost implant
ES2727203T3 (es) * 2011-08-29 2019-10-14 Mati Therapeutics Inc Administración por liberación sostenida de agentes activos para tratar glaucoma e hipertensión ocular
NZ742005A (en) * 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
JP2016515583A (ja) * 2013-03-27 2016-05-30 フォーサイト ヴィジョンファイブ、インク．ＦｏｒＳｉｇｈｔ ＶＩＳＩＯＮ５， Ｉｎｃ． オキュラー・インサートおよびその使用方法

Similar Documents

Publication Publication Date Title
JP2017535592A5 (https=)
MX2015015589A (es) Composiciones y metodos para el suministro de agentes activos hidrófobos.
JP2015514739A5 (https=)
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
BR112015020453A8 (pt) "formas de dosagem de liberação prolongada orais de tofacitinibe e uso de tofacitinibe
JP2011518842A5 (https=)
JP2015523407A5 (https=)
JP2015536939A5 (https=)
BR112015030140A2 (pt) forma de dosagem farmacêutica sólida para liberação de pelo menos um ingrediente farmacêutico ativo na cavidade oral
PE20142035A1 (es) Formulacion compuesta que comprende un comprimido esferoidal de multiples unidades (must) encapsulada en una capsula dura y metodo para preparar la misma
PH12014502331B1 (en) Orally available pharmaceutical formulation suitable for improved management of movement disorders
WO2011140446A3 (en) Pharmaceutical formulations
MX2022005650A (es) Agente terapeutico y agente profilactico para trastornos gastrointestinales funcionales y xerostomia.
MX380361B (es) Suspensiones orales fisica y quimicamente estables de givinostat.
AR092356A1 (es) Formulacion compuesta para administracion oral que comprende metformina y rosuvastatina y metodo de preparacion de la formulacion
JP2015508411A5 (https=)
EP2364733A3 (en) Selegiline-containing adhesive preparation
TWD209758S (zh) 耳機
MX2019004938A (es) Cápsula compleja que contiene esomeprazol y método de preparación de esta.
WO2014181195A3 (en) Antiemetic extended release solid dosage forms
EA029678B9 (ru) Четвертичные соли пиперидиния
WO2011090725A3 (en) Gastroretentive solid oral dosage forms with swellable hydrophilic polymer
JP2020521790A5 (https=)
AR075058A1 (es) Composicion farmaceutica oral para uso en enfermedades respiratorias y proceso de fabricacion
JP2016014215A5 (ja) 花粉付着防止マスクの製造方法